Cargando…

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

BACKGROUND: Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide binding m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Hong, Li, Gai-gai, Nie, Hao, Feng, Yang-yang, Guo, Guang-yu, Guo, Wen-liang, Tang, Zhou-ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023812/ https://www.ncbi.nlm.nih.gov/pubmed/32061264 http://dx.doi.org/10.1186/s12883-020-01633-3

Ejemplares similares

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Correction: Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
por: Muddam, Meghana Reddy, et al.
Publicado: (2023)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines
por: Katsuki, Masahito, et al.
Publicado: (2023)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
por: Hou, Min, et al.
Publicado: (2017)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Monoclonal antibodies for migraine: an update
por: Castle, Daniel, et al.
Publicado: (2018)

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
por: Wang, Xing, et al.
Publicado: (2021)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
por: Pavelic, Antun R., et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review
por: Pervez, Hira, et al.
Publicado: (2020)

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
por: Lu, Jiajie, et al.
Publicado: (2021)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
por: Schoenen, Jean, et al.
Publicado: (2023)

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
por: Fernández-Bravo-Rodrigo, Jaime, et al.
Publicado: (2022)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
por: Giamberardino, Maria Adele, et al.
Publicado: (2017)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis
por: Wang, Xing, et al.
Publicado: (2022)

Efficacy and safety of calcitonin gene‐related peptide antagonists in migraine treatment: A meta‐analysis
por: Huang, Tingting, et al.
Publicado: (2022)

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Calcitonin gene-related peptide causes migraine aura
por: Al-Khazali, Haidar M., et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum]
Publicado: (2018)

Letter to the editor: European headache federation guidelines on the use of monoclonal antibodies acting on the calcitonin gene-related peptide or its receptor for migraine prevention
por: Mikol, Daniel D., et al.
Publicado: (2019)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
por: Wang, Kaicheng, et al.
Publicado: (2023)

Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking
por: Manoukian, Raffi, et al.
Publicado: (2019)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Nichols, Russell, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
por: Szkutnik-Fiedler, Danuta
Publicado: (2020)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis
por: Chen, Yao-Yao, et al.
Publicado: (2021)

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
por: Breen, Ilana D., et al.
Publicado: (2021)

Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine
por: Fila, Michal, et al.
Publicado: (2022)

Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension
por: Yiangou, Andreas, et al.
Publicado: (2020)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
por: Martelletti, Paolo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fcte1r3heafs41as647nm2njfa